property protection for our technology and products; the
ability to enter into, and to maintain, corporate alliances relating to the
development and commercialization of our technology and products; market
acceptance of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued availability of
capital to finance our activities; our ability to continue to integrate
into our business the operations of American Medical Instruments Holdings,
Inc. ("AMI"); our ability to achieve the operational and other synergies
and the other commercial or financial benefits expected as a result of the
acquisition of AMI; and any other factors referenced in our annual
information form and other filings with the applicable Canadian securities
regulatory authorities or the SEC.
Given these uncertainties, assumptions and risk factors, readers are
cautioned not to place undue reliance on such forward-looking statements.
We disclaim any obligation to update any such factors or to publicly
announce the result of any revisions to any of the forward-looking
statements contained in this prospectus to reflect future results, events
or developments.
About Angiotech
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical
and medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases
or complications associated with medical device implants, surgical
interventions and acute injury. To find out more about Angiotech (NASDAQ:
ANPI, TSX: ANP), please visit our website at http://www.angiotech.com.
CONTACT: Jodi Regts, Sr. Manager, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals Inc., (604) 221-7930,
jregts@angio.com; Deirdre Neary, Manager, Investor Relations Angiotech
Pharmaceuticals, Inc. (604) 222-7056, dneary@ang
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
Douglas Stewart reaches distribution pact with digital video firm2.
Avolte Venture Partners reaches capital goal3.
TomoTherapys 100th radiology system reaches public sector4.
Global information firm reaches diverse markets5.
Learning how far your message reaches by Googling yourself6.
Biotech industry reaches midpoint in 50-year maturation cycle7.
Doyle Preaches Importance of Tech Industry at Summit8.
WARF enters licensing agreements for stem cell products9.
Quick peeks, Clawback Agreements, and the rules of electronic discovery10.
Virent enters agreement with Shell Oil unit to make hydrogen with biomass11.
WARF expands license agreement with Advanced Cell Technology